Sodium/Glucose Cotransporter 2 Inhibitors and the Risk of Diabetic Ketoacidosis: An Example of Complementary Evidence for Rare Adverse Events. Issue 8 (6th March 2021)
- Record Type:
- Journal Article
- Title:
- Sodium/Glucose Cotransporter 2 Inhibitors and the Risk of Diabetic Ketoacidosis: An Example of Complementary Evidence for Rare Adverse Events. Issue 8 (6th March 2021)
- Main Title:
- Sodium/Glucose Cotransporter 2 Inhibitors and the Risk of Diabetic Ketoacidosis: An Example of Complementary Evidence for Rare Adverse Events
- Authors:
- Alkabbani, Wajd
Pelletier, Ryan
Gamble, John-Michael - Abstract:
- Abstract: Evidence from observational studies may be considered complementary to that of randomized controlled trials (RCTs), particularly when assessing rare outcomes of drug therapies. Sodium/glucose cotransporter 2 (SGLT-2) inhibitors are a novel class of antidiabetic agents that have been linked to an increased risk of diabetic ketoacidosis (DKA). We conducted a systematic review and separately meta-analyzed data from RCTs ( n = 18; 2013–2019) and cohort studies ( n = 7; 2017–2020) to assess the consistency of the magnitude of association between SGLT-2 inhibitors and DKA risk. We illustrate the strengths and weaknesses of the 2 designs. Results from RCTs and observational studies consistently showed almost a doubling in the risk of DKA among patients using an SGLT-2 inhibitor as compared with placebo or an active comparator. In a random-effects model, the pooled relative risk was 2.08 (95% confidence interval (CI): 1.28, 3.40) from placebo-controlled RCTs and 0.82 (95% CI: 0.25, 2.68) from active-comparator RCTs. The pooled adjusted hazard ratio from observational studies was 1.74 (95% CI: 1.28, 2.38). Notably, the 2 designs complement each other in several domains, including external and internal validity and power. This demonstrates a need for more comprehensive evidence when assessing rare adverse events for both sources.
- Is Part Of:
- American journal of epidemiology. Volume 190:Issue 8(2021)
- Journal:
- American journal of epidemiology
- Issue:
- Volume 190:Issue 8(2021)
- Issue Display:
- Volume 190, Issue 8 (2021)
- Year:
- 2021
- Volume:
- 190
- Issue:
- 8
- Issue Sort Value:
- 2021-0190-0008-0000
- Page Start:
- 1572
- Page End:
- 1581
- Publication Date:
- 2021-03-06
- Subjects:
- adverse events -- diabetic ketoacidosis -- meta-analysis -- rare safety outcomes -- SGLT-2 inhibitors -- sodium/glucose cotransporter 2 -- systematic reviews
Epidemiology -- Periodicals
Public health -- Periodicals
614.4 - Journal URLs:
- http://aje.oxfordjournals.org/ ↗
http://ukcatalogue.oup.com/ ↗ - DOI:
- 10.1093/aje/kwab052 ↗
- Languages:
- English
- ISSNs:
- 0002-9262
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 0824.600000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 18583.xml